{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:58:18Z","timestamp":1794560298675,"version":"4.9.1"},"reference-count":8,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The clinical benefit of adding venetoclax (VEN) to hypomethylating agents or low-dose cytarabine in older and\/or unfit patients with newly diagnosed acute myeloid leukemia (AML) has been confirmed in phase 3 studies. With the increased uptake of VEN-based therapies for patients with AML, a pertinent question is whether treatment can be safely ceased among patients who have achieved sustained remission. We hypothesized that a proportion of patients opting to cease therapy may benefit from a treatment-free remission (TFR) period without indefinite treatment. We report the retrospective outcomes of 29 patients in remission for a minimum of 12 months on VEN-based therapy, with 55% continuing therapy until disease progression and 45% electively ceasing treatment (STOP). With follow-up exceeding 5 years, we observed a median TFR lasting 45.8 months among the STOP cohort, with &amp;gt;50% of patients still in sustained remission at the data cutoff. The risk of relapse and duration of relapse-free and overall survival were similar between the 2 cohorts. Factors favoring sustained TFR within the cohort included NPM1 and\/or IDH2 mutation at diagnosis, complete remission without measurable residual disease, and at least 12 months of VEN-based combination therapy prior to treatment cessation.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007083","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T13:20:44Z","timestamp":1651756844000},"page":"3879-3883","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":70,"title":["Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-3288","authenticated-orcid":false,"given":"Chong Chyn","family":"Chua","sequence":"first","affiliation":[{"name":"1The Alfred Hospital and Monash University, Melbourne, Australia;"},{"name":"2The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Australia;"},{"name":"3Department of Clinical Haematology, Northern Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[{"name":"4University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kent","sequence":"additional","affiliation":[{"name":"5Division of Hematology, University of Colorado School of Medicine, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ing Soo","family":"Tiong","sequence":"additional","affiliation":[{"name":"1The Alfred Hospital and Monash University, Melbourne, Australia;"},{"name":"6Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina Y.","family":"Konopleva","sequence":"additional","affiliation":[{"name":"4University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[{"name":"5Division of Hematology, University of Colorado School of Medicine, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"4University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"1The Alfred Hospital and Monash University, Melbourne, Australia;"},{"name":"2The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Australia;"},{"name":"7Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"issue":"7","key":"2022070515210832400_B1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med."},{"issue":"24","key":"2022070515210832400_B2","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood."},{"key":"2022070515210832400_B3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol."},{"issue":"15","key":"2022070515210832400_B4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022070515210832400_B5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/bloodadvances.2020003902","article-title":"Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv."},{"issue":"2","key":"2022070515210832400_B6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"2022070515210832400_B7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."},{"issue":"23","key":"2022070515210832400_B8","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1002\/cncr.32439","article-title":"Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: a population-level analysis","volume":"125","author":"Zeidan","year":"2019","journal-title":"Cancer."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/13\/3879\/1905026\/advancesadv2022007083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/13\/3879\/1905026\/advancesadv2022007083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T11:22:11Z","timestamp":1657020131000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/13\/3879\/485175\/Treatment-free-remission-after-ceasing-venetoclax"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":8,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,7,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007083","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]}}}